Risk Factors for Cytomegalovirus Viremia and Disease Developing after Prophylaxis in High-Risk Solid-Organ Transplant Recipients
- 1 December 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 78 (12) , 1765-1773
- https://doi.org/10.1097/01.tp.0000142619.01510.a5
Abstract
Cytomegalovirus (CMV) D+/R− solid-organ transplant (SOT) recipients carry increased risk of developing CMV disease; however, other risk factors in these patients have not been delineated. We examined 20 demographic and clinical variables for their association with the development of CMV disease, as defined by an independent endpoint committee (IEC) and also by the investigator (investigator treated [IT]), or CMV viremia within 12 months of transplant in D+/R− transplant recipients who received prophylaxis with valganciclovir or oral ganciclovir for 100 days. Recipients with low creatinine clearance (Ccr,<40 mL/min) at screening had a significantly increased hazard of developing IEC-defined CMV disease (hazards ratio [HR]=4.28, confidence interval [CI] 1.69, 10.83). Females were twice as likely (HR=2.19, CI .21, 3.99) to develop IEC-defined CMV disease than males. These variables were associated with an increased risk of IEC-defined CMV disease in time-dependent models. Recipients with blood group A were also more likely to develop IEC-defined CMV disease than those with group O (HR=2.36 CI 1.24, 4.51) in the logistic regression model only. Prophylactic drug, organ type, recipient age, rejection episodes, and maintenance immunosuppression regimen were not associated with IEC-defined CMV disease. Female sex was the only variable associated with the development of CMV viremia (odds ratio [OR]=1.65; CI 1.03, 2.65) and IT CMV disease (OR=1.78; CI 1.08, 2.93). Low Ccr at screening and blood type A are risk factors for IEC-defined CMV disease, and female sex was a risk factor for IEC- and IT-defined CMV disease and viremia in high-risk SOT recipients. These variables should perhaps be considered when optimizing treatment.Keywords
This publication has 22 references indexed in Scilit:
- Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2004
- Cytomegalovirus Disease after Prophylaxis with Oral Ganciclovir in Renal TransplantationJournal of the American Society of Nephrology, 2003
- The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV diseaseTransplantation, 2002
- Allograft Rejection Predicts the Occurrence of Late‐Onset Cytomegalovirus (CMV) Disease among CMV‐Mismatched Solid Organ Transplant Patients Receiving Prophylaxis with Oral GanciclovirThe Journal of Infectious Diseases, 2001
- Comparative Quantitation of Cytomegalovirus (CMV) DNA in Solid Organ Transplant Recipients with CMV Infection by Using Two High-Throughput Automated SystemsJournal of Clinical Microbiology, 2001
- Cytomegalovirus Infection in Immunocompetent and Immunocompromised Individuals - A ReviewCytomegalovirus Infection in Immunocompetent and Immunocompromised Individuals - A ReviewCurrent Drug Target - Immune, Endocrine & Metabolic Disorders, 2001
- Prevention and treatment of cytomegalovirus disease in heart transplant patientsPublished by Elsevier ,2000
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationNew England Journal of Medicine, 1999
- Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3Antimicrobial Agents and Chemotherapy, 1995
- The Indirect Effects of Cytomegalovirus Infection on the Outcome of Organ TransplantationJAMA, 1989